-
Mono-ADP-Ribosylation Marks PARP7 and AHR for Degradation
2026-09-04
The reference study shows that blocking ubiquitylation or proteasomal turnover exposes endogenous ADP-ribosylated proteins that are otherwise rapidly degraded. It identifies DTX2 as the E3 ligase controlling degradation of ADP-ribosylated PARP7, AHR, and related substrates, establishing mono-ADP-ribosylation as a physiologically relevant degradation signal.
-
Nicotine Signaling in Chronic Kidney Disease
2026-09-04
This review synthesizes clinical and experimental evidence that nicotine contributes to chronic kidney disease progression through non-neuronal nicotinic acetylcholine receptors, oxidative stress, hemodynamic changes, and pro-fibrotic signaling. Its principal contribution is a mechanistic framework linking smoking-associated renal deterioration to nicotine biology while distinguishing nicotine effects from the broader chemical complexity of cigarette smoke.
-
PA-824: From Nitro-Reduction to TB Assay Design
2026-09-04
PA-824 is a bicyclic nitroimidazole derivative whose activity links mycolic-acid disruption with respiratory collapse in Mycobacterium tuberculosis. This article explains how that biology should shape phenotype-aware assays, combination studies, and interpretation of drug-tolerant populations.
-
v-Agatoxin-IVA and N-Type Ca Channel Selectivity
2026-09-03
Sidach and Mintz showed that v-Agatoxin-IVA, widely used as a high-selectivity P-type calcium channel probe, can also produce incomplete, low-affinity blockade of neuronal N-type currents. The work demonstrates why toxin concentration, channel gating, and cellular context must be considered when assigning pharmacological channel identities.
-
Engineering a Focused Bitespiramycin Producer
2026-09-02
The reference study used an in-frame partial deletion of the sspA 3-O-acyltransferase gene to redirect a complex bitespiramycin biosynthetic profile toward 400-isovalerylspiramycin I. Its strain-engineering strategy illustrates how targeted tailoring-enzyme disruption can simplify antibiotic composition and improve the interpretability of downstream production and susceptibility studies.
-
ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors
2026-09-02
Pladevall-Morera and colleagues used an ATRX-stratified drug screen to identify receptor tyrosine kinase and PDGFR inhibitors as selectively more toxic to ATRX-deficient high-grade glioma cells. The study also shows that combining these inhibitors with temozolomide may enhance treatment response, supporting ATRX status as a relevant variable in translational studies and clinical-trial analyses.
-
Cefoperazone Sodium Salt: Assay Workflows
2026-09-01
Build more informative antimicrobial experiments with Cefoperazone sodium salt by combining MIC, MBC, β-lactamase-stratified testing, and biliary-matrix models. This practical guide covers preparation, assay design, comparative interpretation, and troubleshooting for gram-negative bacterial research.
-
Staurosporine: Designing Interpretable Death Assays
2026-09-01
Staurosporine is a broad-spectrum serine/threonine protein kinase inhibitor widely used to induce apoptosis and interrogate cancer signaling. This guide presents a context-aware assay framework that distinguishes kinase perturbation from cell-death response, with practical implications for cancer research and liver disease models.
-
Nadolol (SQ-11725) in Cardiovascular Research
2026-08-31
Nadolol (SQ-11725) combines non-selective beta-adrenergic receptor blockade with a useful transporter and tissue-distribution question for cardiovascular models. This workflow shows how to connect beta-adrenergic signaling pathway assays with exposure measurements, controls, and troubleshooting for more interpretable hypertension research, angina pectoris studies, and vascular headache research.
-
BX795 PDK1 Inhibitor Workflows for Kinase Research
2026-08-31
BX795 combines nanomolar PDK1 activity with experimentally useful TBK1 and IKKε engagement, making it valuable for separating kinase signaling, cancer phenotypes, and innate immune readouts. This workflow-centered guide explains how to apply it without confusing pathway inhibition, cytostasis, and cell death.
-
Selective Autophagy Tunes IRF3 Stability
2026-08-30
Wu and colleagues show that CALCOCO2/NDP52-dependent selective autophagy removes IRF3 in a virus-load-dependent manner, while PSMD14 preserves IRF3 by editing its ubiquitin signal. The study defines a quality-control circuit that balances type I interferon production with immune suppression and offers a useful framework for analyzing transcription-factor turnover.
-
One-step TUNEL Cy3 Apoptosis Detection Kit Workflow
2026-08-29
Build a reproducible DNA fragmentation assay for tissue sections, adherent cells, suspension cells, and flow cytometry with a Cy3-based one-step workflow. Practical controls, quantitative readouts, and troubleshooting guidance help distinguish genuine apoptotic signaling from preparation artifacts.
-
ABT-199 Workflows for Mitochondrial Apoptosis
2026-08-28
Build sharper apoptosis assays with ABT-199 (Venetoclax), a highly selective BCL-2 probe for separating BCL-2 dependence from broad cytotoxicity. This workflow connects concentration-response profiling in lymphoma and AML models with the emerging evidence that RNA Pol II loss can actively signal to mitochondria.
-
EPZ5676: Practical DOT1L Inhibitor Workflows
2026-08-28
EPZ5676 combines subnanomolar biochemical potency with exceptional DOT1L selectivity, making it useful for both enzyme-level validation and cell-based epigenetic studies. This guide translates its mechanism into reproducible H3K79 methylation, leukemia cytotoxicity, and innate immune signaling workflows.
-
Actinomycin D: Mechanism, Uses & Protocol Limits
2026-08-27
Actinomycin D, also called ActD, is a DNA-intercalating transcriptional inhibitor used in cancer research, mRNA stability assays, and studies of transcriptional stress. Its global suppression of RNA synthesis supports apoptosis induction studies but also creates important limits for target-specific interpretation.